Corporate News

Investor presentation

19 July 2021

GENinCode plc, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces Matthew Walls, CEO and Paul Foulger, CFO will provide a live investor presentation via the Investor Meet Company platform at 10am BST on Thursday, 22 July 2021.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via: https://www.investormeetcompany.com/genincode-plc/register-investor

Investors who already follow GENinCode plc on the Investor Meet Company platform will automatically be invited.

 

For further information please contact:

GENinCode plc

www.genincode.com

Matthew Walls, CEO

Via Walbrook PR

Paul Folger, CFO




Stifel Nicolaus Europe Limited (NOMAD and Sole Broker)

Tel: +44 (0)20 7710 7600

Alex Price / Richard Short




Walbrook PR Limited

Tel: 020 7933 8780 or genincode@walbrookpr.com

Anna Dunphy / Paul McManus / Louis Ashe-Jepson


 

About GENinCode plc

GENinCode plc is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in certain European countries and is also targeting the UK and US.

Latest Share Price

-
-
-

Financial Calendar

Annual General Meeting 23 June 2022

Board

Who Are We

Governance

Investor Alerts

GENinCode UK Limited
Oxford Science Park
John Eccles House
Robert Robinson Avenue
Oxford - UK
OX4 4GP
(+44) 186 5955 847
GENinCode S.L.U.
Rambla Egara, 235, ES- 08224
Terrassa-Barcelona
Spain
(+34) 936 690 321